ClinicalTrials.gg
RecruitingNCT06409624Updated Sep 8, 2026

Association Between Biomarkers and Kidney Function Decline in Pulmonary Hypertension

An observational study in Pulmonary Hypertension and Chronic Kidney Disease, sponsored by University of Giessen. Recruiting at 2 sites in Germany. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-09-08.

Sponsored by University of Giessen · Observational

How we know

From the registry’s dates

  • Started May 2024; still recruiting 2 years 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
400
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 13 studies in Hypertension, Pulmonary by University of Giessen — 5 open to participants now, 5 under way, none of them phase 3. Hypertension, Pulmonary · University of Giessen.

Planned enrollment
8th of 11
400 · median 500
Started
2024
the only one that year
Observational
11 of 13
5 open now
Registered
13th of 13
by date

Among the 13 studies in Hypertension, Pulmonary by University of Giessen, this one is the 8th largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2024, is one of 11 observational ones, and was the 13th registered.

Hypertension, Pulmonary

1,092 studies on the registry are indexed under Hypertension, Pulmonary; 243 are open to participants now.

Browse Hypertension, Pulmonary studies →

Open to participants now

5 of the 13 studies in Hypertension, Pulmonary by University of Giessen are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 163 Hypertension, Pulmonary studies recruiting now, 98 (60%) set no upper age limit and 26 (16%) stop at 75 or younger; 38 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 13 studies in Hypertension, Pulmonary by University of Giessen, or all of them as a file.
02

Study summary

The objective of this study is to examine the association between urinary and plasma biomarkers and change in estimated glomerular filtration rate (eGFR) among patients with pulmonary hypertension (PH).

Read the detailed description

PH is a severe, progressive disease associated with right ventricular dysfunction, right-sided heart failure (HF) and death. Kidney disease is present in approximately 35% of patients with PH, and its presence is associated with an enhanced risk for adverse outcomes, with the risk increasing incrementally with declining kidney function. Poor right ventricular function may increase venous congestion, alter ventricular interdependence, decrease effective cardiac output and activate the renin-angiotensin- aldosterone system, thereby aggravating kidney disease.

There is a crucial need to better understand the pathophysiological mechanisms linking the failing right heart and the kidney. To date, diagnostic and prognostic biomarkers of kidney disease in PH are lacking. The objective of this study is to examine the association between urinary and plasma biomarkers and change in eGFR among patients with PH.

03

Conditions studied

  • Pulmonary Hypertension
  • Chronic Kidney Disease
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes
Sampling method
Probability sample

Study population

Inpatients admitted at University Hospital Giessen and Marburg, Campus Giessen and Kerckhoff Klinik Bad Nauheim with suspected or pre-diagnosed PH undergoing RHC

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Inpatients aged ≥18 years
  • Undergoing right heart catheterization (RHC)

Exclusion criteria

Exclusion Criteria:

  • multifactorial or indeterminate PH, for which no single underlying mechanism could be reliably classified
  • active tumor disease requiring targeted therapy
  • inflammatory or disease with renal involvement requiring systemic treatment
  • unexplained kidney function decline, defined as serum creatinine increase ≥0.5 mg/dL from baseline within the prior 7 days before RHC
  • Chronic kidney disease with \<20 ml/min/1.73 m2
  • non-kidney failure requiring extracorporeal or peritoneal ultrafiltration for diuretic-resistant volume overload
  • if they had received non-steroidal anti-inflammatory drugs or intravenous contrast within 72 hours before RHC
  • prediagnosed glomerulonephritis
  • polycystic kidney disease
  • postrenal obstruction
  • single kidney (functional or anatomical)
  • solid organ transplantation
  • anticipated of \<12 months
  • likelihood of receiving advanced therapy (mechanical circulatory assist device/lung or cardiac transplant)
  • pregnancy or possibility of pregnancy in the next 12 months
  • inability to cooperate with respiratory maneuvers during renal Doppler
  • refusal to participate
  • not available for follow-up visits
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
400 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna

Groups and cohorts

  • Pulmonary hypertension

    Patients with diagnosed PH by right heart catheterization with or without PH-specific treatment

    Other: No intervention is planned as part of the study

  • No pulmonary hypertension

    Patients in whom PH was excluded by right heart catheterization

    Other: No intervention is planned as part of the study

Interventions

  • OtherNo intervention is planned as part of the study

    No intervention is planned as part of the study

06

What researchers measure

Primary outcomes

  1. Major adverse kidney events

    Number of patients experiencing ≥q of the individual outcomes of the composite outcome of eGFR decline ≥25%, initiation of dialysis, or kidney-related death

    Time frame: Baseline to 12 months

  2. Worsening PH or HF

    Number of patients experiencing worsening of PH, defined as hospitalization due to acute right heart failure, increase in PH-targeted medication or diuretics (outpatient or inpatient), or worsening of PH as diagnosed by right heart catheterization

    Time frame: Baseline to 12 months

Secondary outcomes

  1. All-cause mortality

    Number of patients experiencing all-cause mortality during follow-up

    Time frame: Baseline to 12 months

  2. Kidney function decline

    Number of patients with 50% decline in eGFR from baseline and the eGFR slope at 12 months

    Time frame: 12 months

  3. Pulmonary hypertension-related death

    Death attributed to pulmonary hypertension

    Time frame: 12 months

07

Study locations

2 of 2 sites recruiting
  • Kerckhoff Klinik Heart and Thorax Center
    Bad Nauheim, Hesse, Germany
    Recruiting
  • University Hospital Giessen and Marburg, Campus Giessen, Department of Internal Medicine II
    Giessen, Hesse 35392, Germany
    Recruiting
08

References and documents

Publications

  • Husain-Syed F, DiFrancesco MF, Deo R, Barr RG, Scialla JJ, Bluemke DA, Kronmal RA, Lima JAC, Praestgaard A, Tracy RP, Shlipak M, Kawut SM, Kim JS. Associations between eGFR and albuminuria with right ventricular measures: the MESA-Right Ventricle study. Clin Kidney J. 2023 Apr 21;16(9):1508-1520. doi: 10.1093/ckj/sfad096. eCollection 2023 Sep. PubMed 37664568 ↗
  • Chakinala MM, Coyne DW, Benza RL, Frost AE, McGoon MD, Hartline BK, Frantz RP, Selej M, Zhao C, Mink DR, Farber HW. Impact of declining renal function on outcomes in pulmonary arterial hypertension: A REVEAL registry analysis. J Heart Lung Transplant. 2018 Jun;37(6):696-705. doi: 10.1016/j.healun.2017.10.028. Epub 2017 Nov 6. PubMed 29174533 ↗

Individual participant data

Plan to share: Undecided

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2024 (actual). Primary completion is estimated for Oct 2027, 41 months after the start.

Of 142 non-industry observational studies under Hypertension, Pulmonary, half reached primary completion within 60 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 167. This study's planned 41 months is below that.

Counting every sponsor, half of 167 studies reached it within 59 months; a quarter within 24 and three quarters within 107.

How these figures are worked out, and which studies are left out of them.

Registered
May 7, 2024
First posted
May 10, 2024
StartActual
May 31, 2024
Primary completionEst.
Oct 2027
CompletionEst.
Dec 2027
Last update
Sep 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06409624
Lead sponsor
University of Giessen
Responsible party
Sponsor
First posted
May 10, 2024
Start date
May 31, 2024
Primary completion
Oct 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Sep 8, 2026

Study contacts

Faeq Husain-Syed, MD
Contact
faeq.husain-syed@innere.med.uni-giessen.de
+49 641 985 42378
Birgit Jennert, MLA
Contact
birgit.jennert@innere.med.uni-giessen.de
+49 641 985 42378
Faeq Husain-Syed, MD
principal investigator · University of Giessen

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion